58 Real-life single-centre experience of Tocilizumab-associated neutropenia in children with juvenile idiopathic arthritis (JIA)

BackgroundTocilizumab, approved for treatment of children with Systemic-onset-JIA (SoJIA) and polyarticular-JIA (pJIA) is efficacious and well-tolerated. Transient neutropenia is a side-effect of treatment.AimChart-review of children treated with Tocilizumab to report on Tocilizumab-associated-neuto...

Full description

Saved in:
Bibliographic Details
Published in:Archives of disease in childhood 2019-11, Vol.104 (Suppl 4), p.A23
Main Authors: Foley, Charlene, Fearon, Ursula, Obaidi, Muthana Al
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundTocilizumab, approved for treatment of children with Systemic-onset-JIA (SoJIA) and polyarticular-JIA (pJIA) is efficacious and well-tolerated. Transient neutropenia is a side-effect of treatment.AimChart-review of children treated with Tocilizumab to report on Tocilizumab-associated-neutopenic-episodes.MethodsRetrospective review of patients receiving Tocilizumab (January 2010-January 2019). Patients with extended-oligoarticular-JIA (ExO-JIA), pJIA and SoJIA reviewed in more detail to ascertain frequency of neutropenia and related-factors. For analysis, ExO-JIA and pJIA were combined to create an ExO/pJIA group. Neutropenia defined as neutrophils
ISSN:0003-9888
1468-2044
DOI:10.1136/archdischild-2019-gosh.58